Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive's Stephen Gunnion about the company’s strong presence at BIO-Europe 2025 and the growing momentum behind its late-stage clinical programs. The conversation centred on the progress of its lead asset vidofludimus calcium, particularly its ongoing ENSURE Phase 3 trials for relapsing multiple sclerosis, which are fully enrolled and expected to report data at the end of 2026. Vitt described the Vienna-based conference as “a very exciting, active, energetic meeting” and highlighted its international scope. He noted that while Immunic is US-focused, BIO-Europe provided valuable networking opportunities within the European investor and biotech community. Much of the investor and partner interest at the event was directed towards Immunic’s multiple sclerosis program. “It’s a unique growth story and has the ability to address here a multi-billion market opportunity,” said Vitt, referring to vidofludimus calcium, which he described as “a dual acting molecule” and “first in class Nurr-1 activator.” In addition, Vitt pointed to continued progress in Immunic’s gastrointestinal program, IMU-856, which has shown promising early clinical data in celiac disease and GLP-1 upregulation. The company is exploring further development and potential partnerships for this asset. For more biotech updates and executive insights, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel and enable notifications for future content. #Immunic #MultipleSclerosis #VidofludimusCalcium #IMU856 #BiotechNews #BIOEurope2025 #ClinicalTrials #PharmaUpdate #CeliacDisease #MSResearch #HealthcareInvesting